We are a life sciences investment bank specializing in mergers and acquisitions, licensing/partnership transactions, and private placements.


On each transaction, we devote a senior team of bankers committed to a transparent, thoughtful approach to success. Our collective life science banking experience includes:

Advising on more than $15 billion in M&A and partnering transactions; raising over $8 billion in capital.

Maintaining top-tier relationships throughout the global life science industry.

Biotechnology, big pharma, specialty pharma, medical devices, research tools and diagnostics.



We are a life sciences investment bank specializing in mergers and acquisitions, licensing/partnership transactions, and private placements.

On each transaction, we devote a senior team of bankers committed to a transparent, thoughtful approach to success. Our collective life science banking experience includes:

Our Proven Track Record

Click on one of the images below to view a recent transaction

Select Transactions


Partnering
4 pieris

Collaboration with AstraZeneca to develop and commercialize Anticalin-based inhaled treatments for respiratory diseases.

24 vivus

Under the Menarini, Auxilium and Sanofi agreements, avanafil is expected to be commercialized in over 100 countries worldwide.

28 onconova

One of the largest licensing deals to date solely for European rights to a drug candidate.

38 medivation

Buyside representation of Medivation on the in-licensing of an anti-PD-1 immune modulatory monoclonal antibody from CureTech Ltd.


Sell Side
6 concert

The asset acquisition supplemented Vertex's pipeline portfolio of cystic fibrosis assets in development.

14 xlumena

Sale of a privately held, venture-backed, GI company with strong early commercial traction.

25 ceptaris

Sale of privately held, specialty pharmaceutical company with FDA-approved orphan drug for early stage mycosis fungoides.

27 nextwave

Aquilo introduced Pfizer and NextWave, and assisted NextWave in evaluating and negotiating the option and merger agreement.


Buy Side
7 tersera

TerSera Therapeutics entered into an agreement with AstraZeneca for the commercial rights to Zoladex in the US and Canada.

9 hoya

Ophthalmic eyewear lenses is the largest business unit in HOYA’s Life Care segment.

17 medivation

Medivation was developing enzalutamide, a novel, oral anti-androgen drug candidate for prostate cancer.

20 hepalink

Buyside representation on the acquisition of leading global manufacturer and supplier of active pharmaceutical ingredients.


Private Placement
2 amphora

Funding for pivotal study and FDA approval for novel cystoscopic device that has the potential to improve bladder function in OAB patients.

11 dalcor

Late-stage precision medicine company developing dalcetrapib to be the first genetically targeted medicine in cardiovascular disease

19 omni

Funding will be used immediately to fund OMNI’s growth initiatives, including expansion of OMNI’s hip and knee product lines

29 onconova

One of the largest licensing deals to date solely for European rights to a drug candidate.


Office Locations

san-francisco-locationsf-map

San Francisco
One Maritime Plaza, 15th Floor
San Francisco, CA, 94111
(415) 677-9773
info@aquilopartners.com

new-york-locationny-map

New York
888 Seventh Avenue, 12th Floor
New York, NY 10106
(646) 942-5623
info@aquilopartners.com

boston-locationboston-map

Boston
101 Main Street, 14th Floor
Cambridge, MA 02142
(617) 401-2483
info@aquilopartners.com

Office Locations

Member FINRA / SIPC